# COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).

> **NCT05252468** · NA · COMPLETED · sponsor: **Nasus Pharma** · enrollment: 693 (actual)

## Conditions studied

- COVID-19
- Upper Respiratory Tract Infections

## Interventions

- **DEVICE:** TaffiX™

## Key facts

- **NCT ID:** NCT05252468
- **Lead sponsor:** Nasus Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-19
- **Primary completion:** 2021-11-02
- **Final completion:** 2021-12-02
- **Target enrollment:** 693 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05252468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05252468, "COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05252468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*